ASH2023 - Sheba 2.0, page-68

some transactions involving AbbVie

Pharmacyclics - AbbVie acquired Pharmacyclics in 2015 for approximately $21 billion. This deal brought Imbruvica, a breakthrough therapy for certain types of blood cancers, fully into AbbVie’s portfolio. My benchmark

Allergan - The acquisition of Allergan by AbbVie was completed in May 2020 for a deal valued at about $63 billion. This acquisition expanded AbbVie's portfolio with a range of products, including Botox, Vraylar, Ubrelvy, and Juvederm.

Stemcentrx - AbbVie purchased Stemcentrx in 2016 for $5.8 billion upfront, with additional milestone payments potentially bringing the total deal value to $10.2 billion. This deal was aimed at expanding AbbVie’s oncology portfolio, particularly gaining the drug Rova-T (rovalpituzumab tesirine), which was under investigation for small cell lung cancer.

Mavupharma - In 2019, AbbVie acquired Mavupharma, a private biopharmaceutical company. The financial terms of this deal were not disclosed.